Covid-19 roundup: Inovio enlists plasmid manufacturer to replace the one it's in legal feud with; Cyberattacks spotted targeting vaccine distribution
With its Phase II trial finally underway, Inovio has enlisted another key manufacturing partner to hit its goal of hundreds of millions of doses of its DNA vaccine — filling the role of a contract manufacturer it’s still in a legal standoff with.
Japan’s Kaneka Eurogentec is tasked with plasmid production, for which Inovio has previously relied on Korean-owned VGXI. It joins a consortium Inovio has assembled that includes Thermo Fisher Scientific, Richter-Helm BioLogics and Ology Bioservices.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,500+ biopharma pros reading Endpoints daily — and it's free.